Monkeypox vaccine: ‘We must make full use of the vaccine in high-risk groups’

Whether it is excess or deficiency, vaccine They are the center of attention. World Health Organization (WHO) Global Public Health Emergencies The shortcomings and needs are exposed to everyone Glutenformerly known as Monkeypox.

Doctors Without Borders (MSF) calls for Vaccine donation“We must now make full use of the vaccine among the most at-risk and most vulnerable groups,” said Francisco Bartolomé, technical adviser for tropical diseases at Doctors Without Borders.

Danish pharmaceutical lab may have a point Bavaria Northern EuropeManufacturer Vaccines to prevent infection Yesterday it was announced that a request had been made to the European Medicines Agency (EMA) Expand its use to adolescents aged 12 to 17“Given that we are tracing the transmission routes of the virus, where close contact with skin lesions and fluids is key, we must find forms of protection for everyone.”

It has already appeared in African countries Large numbers of children affectedrepresent Earthquakes caused more than 70% of smallpox cases and 85% of deaths In the Democratic Republic of Congo, Bartolomé said: “We have to confirm whether mothers are transmitting the virus to their babies through breast milk or breast lesions. We also have to address the issue of care for infected people without creating stigmatizing isolation.”

Bavaria Nordic guarantees that it has Reserve about 500,000 doses Up to 10 million doses of the vaccine could be produced by 2025. The European Health Emergency Preparedness and Response Agency (HERA) has announced Donated 215,000 doses of vaccineand supporting the African Union health agency in diagnosing and sequencing the virus.

In Spain, the same is true for health 20,900 vaccinated Spaniards were askedwho completed the vaccination program. According to data collected by the Health Vaccination Registry (REGVACU), of the 40,610 people who received the monkeypox vaccine, only half received both vaccines, despite belonging to the highest risk group.

What does the Monkeypox Vaccine Shield look like?

By publishing in Cell Host and MicroorganismThe scientists investigated the sensitivity of MPOX to neutralizing antibodies (defenses responsible for repelling pathogens) produced after infection with the virus and/or vaccination with the Imvanex vaccine developed in a Danish laboratory. The vaccine has been used as pre- and post-exposure prophylaxis in high-risk groups, but its effectiveness has not been fully characterized.

Scientists and doctors from the Institut Pasteur, CNRS, Inserm, VRI and the Paris Public Hospital Network (AP-HP) studied 470 sera from individuals vaccinated or infected with the human immunodeficiency virus MPOX to look for the mechanisms involved and determine the protection against infection or the severity of the disease.

One striking data point was that the highest levels of antibodies were found in individuals born before 1980 (and therefore vaccinated against smallpox), both after infection and after taking Imvanex. This highlights the impact of historical vaccination on the immune response to infection or puncture. A mixed immune Among infected people who were vaccinated during childhood.

Since mass smallpox vaccination was stopped in the 1980s, the number of MPOX infections has increased steadily. Help define the relevance of protection Olivier Schwartz, head of the Virus and Immunity Unit at the Institut Pasteur and last author of the study, commented in the abstract of the publication.

“Prose can also For epidemiological investigationsassess the duration of protection conferred by previous infection or authorized and candidate vaccines, and analyze the use of immunotherapeutic interventions. “They are a useful tool to understand the mechanisms of viral reproduction,” emphasizes Schwartz.